Pamela Esposito has held a variety of strategy, commercial and business development positions in small biotech companies over the past 15 years, playing lead roles in transformative deals for each company, including in her current role as Chief Business Officer of Replimune. Previously, Pamela was Chief Business Officer at Ra Pharmaceuticals where she played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. In addition to serving on Accent’s board of directors, Pamela sits on the board of directors of Kymera Therapeutics, Inc. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.